Form 4: Xenon Pharmaceuticals Director Justin Gover Granted Significant Equity Awards

Xenon Pharmaceuticals Inc. Director Justin D. Gover was granted 17,012 share options and 2,645 restricted share units on June 5, 2025, as reported in a recent SEC Form 4 filing.

Summary

• Justin D. Gover, a Director of Xenon Pharmaceuticals Inc. (XENE), acquired new equity awards as part of his compensation.
• On June 5, 2025, Mr. Gover was granted 17,012 share options with an exercise price of $30.73 per share.
• These share options are set to vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders, and have an expiration date of June 4, 2035.
• Additionally, Mr. Gover was granted 2,645 Restricted Share Units (RSUs), each representing a contingent right to receive one Common Share.
• The RSUs will also vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.
• Following these transactions, Mr. Gover directly beneficially owns 17,012 share options and 2,645 Restricted Share Units.

Sentiment

Score: 7

Explanation: The granting of equity awards to a director is generally viewed positively as it aligns management's interests with shareholders and is a standard component of executive compensation, indicating stability and retention efforts.

Positives

• The granting of share options and restricted share units to Director Justin D. Gover aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• These equity awards represent a commitment to retaining key leadership within Xenon Pharmaceuticals Inc., which can contribute to stability and continuity in governance.

Future Outlook

The vesting schedule for the equity awards, extending to June 2026, indicates a forward-looking incentive structure designed to retain the director and align his performance with the company's long-term objectives and shareholder value creation.

Industry Context

The granting of equity awards to directors is a common and standard practice in the biotechnology and pharmaceutical industry. This strategy is widely used to attract, retain, and incentivize key talent, aligning their compensation with company performance and fostering long-term shareholder value creation.

Related Party Transactions

• The granting of share options and restricted share units to Justin D. Gover, a Director of Xenon Pharmaceuticals Inc., constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with shareholder value through equity ownership and long-term incentives.

Next Steps

• Vesting of 17,012 share options and 2,645 Restricted Share Units on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.
• Potential exercise of the share options by Mr. Gover at the exercise price of $30.73, subject to vesting.

Key Dates

Recommendation

Keywords

Xenon Pharmaceuticals, XENE, Form 4, insider transaction, equity awards, share options, restricted share units, director compensation, beneficial ownership